LÉO RAMOS Recepta’s monoclonal antibodies undergo testing at the Butantan InstituteLÉO RAMOS
Small firms working jointly with large pharmaceutical companies are helping to enhance studies of immunotherapy drugs that have a potential for use in cancer treatment. The journal Nature Biotechnology published a worldwide profile of this sector in its March 2013 issue. The acquisition of the small biotech firm Medarex by the U.S. company Bristol-Myers Squibb and the partnership formed between Britain’s GlaxoSmithKline and two U.S. groups (the MD Anderson Cancer Center at the University of Texas and the company Amplimmune) were two of the endeavors mentioned in the article. The journal also cited the Brazilian firm Recepta Biopharma for its development of immunomodulatory monoclonal antibodies, which promote an increased immune response in patients. Prof. José Fernando Perez, former science director at FAPESP, serves as the CEO of Recepta, whose head offices are located in São Paulo. The company has signed cooperation agreements with São Paulo’s Butantan Institute and the Ludwig Institute for Cancer Research in New York. Earlier this year, Recepta also signed a partnership agreement with 4-Antibody AG, a Swiss firm that holds the technology to generate and reproduce human antibodies faster and more safely.
Republish